Dupixent Lawsuit: Litigation Update and Settlement Information

Start
Cutaneous T-cell lymphoma (CTCL) is a rare and aggressive form of cancer that has been linked to the drug Dupixent in some cases. Dupixent is prescribed to asthma patients as well as for treatment of chronic obstructive pulmonary disease (COPD), chronic sinusitis, nasal polyps, eosinophilic esophagitis, and moderate to severe eczema (atopic dermatitis). Patients diagnosed with CTCL after taking Dupixent have begun filing lawsuits related to their Dupixent use, and Dupixent patients who have not…
By: Oberheiden P.C.
Previous Story

Arbitration and AI: From Data Processing to Deepfakes. Outlining the Potential–and Pitfalls–of AI in Arbitration

Next Story

First Dupixent Lawsuit Filed Over Fatal Lymphoma: What It Means for Patients and Families